Advertisement

Topics

Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

15:42 EST 17 Feb 2018 | Topix

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. He said it did not meet a requirement that it disclose how to make and use the treatment it covered without undue experimentation.

Original Article: Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

NEXT ARTICLE

More From BioPortfolio on "Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict"

Advertisement
Quick Search
Advertisement
Advertisement